Paul Badawi Sells 24,174 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 24,174 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total value of $55,600.20. Following the sale, the chief executive officer now directly owns 6,010,580 shares of the company’s stock, valued at $13,824,334. The trade was a 0.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Paul Badawi also recently made the following trade(s):

• On Thursday, January 16th, Paul Badawi sold 24,819 shares of Sight Sciences stock. The stock was sold at an average price of $2.92, for a total value of $72,471.48.

Sight Sciences Stock Performance

NASDAQ SGHT opened at $2.30 on Friday. The company’s 50 day moving average is $2.67 and its 200-day moving average is $3.86. The firm has a market cap of $118.07 million, a P/E ratio of -2.25 and a beta of 2.52. Sight Sciences, Inc. has a 12-month low of $2.04 and a 12-month high of $8.45. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36.

Sight Sciences (NASDAQ:SGHT) last posted its earnings results on Wednesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The company had revenue of $19.07 million for the quarter, compared to analysts’ expectations of $18.98 million. During the same quarter in the prior year, the company earned ($0.22) EPS. Sell-side analysts predict that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analyst Weigh In

SGHT has been the subject of several research analyst reports. Citigroup decreased their target price on Sight Sciences from $4.60 to $3.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Piper Sandler decreased their price objective on shares of Sight Sciences from $5.50 to $3.50 and set a “neutral” rating for the company in a report on Thursday, March 6th. Lake Street Capital dropped their target price on shares of Sight Sciences from $3.00 to $2.50 and set a “hold” rating on the stock in a research note on Thursday, March 6th. UBS Group decreased their price target on shares of Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a research note on Monday, January 27th. Finally, Stifel Nicolaus lowered their price target on shares of Sight Sciences from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $3.83.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Sight Sciences by 46.3% in the third quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company’s stock worth $1,310,000 after buying an additional 65,767 shares in the last quarter. State Street Corp increased its holdings in Sight Sciences by 17.4% during the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock worth $4,075,000 after acquiring an additional 95,843 shares during the period. Barclays PLC increased its holdings in Sight Sciences by 317.4% during the 3rd quarter. Barclays PLC now owns 50,300 shares of the company’s stock worth $317,000 after acquiring an additional 38,248 shares during the period. Geode Capital Management LLC lifted its stake in Sight Sciences by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after purchasing an additional 12,709 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. boosted its holdings in Sight Sciences by 5.4% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company’s stock valued at $1,174,000 after purchasing an additional 10,000 shares during the period. Institutional investors own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.